Cargando…

5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo

BACKGROUND/AIMS: Nephrotoxicity is a frequent and major limitation in cisplatin (CDDP)-based chemotherapy. 5-Aminolevulinic acid (ALA) is widely distributed in animal cells, and it is a precursor of tetrapyrole compounds such as heme that is fundamentally important in aerobic energy metabolism. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Terada, Yoshio, Inoue, Keiji, Matsumoto, Tatsuki, Ishihara, Masayuki, Hamada, Kazu, Shimamura, Yoshiko, Ogata, Koji, Inoue, Kosuke, Taniguchi, Yoshinori, Horino, Taro, Karashima, Takashi, Tamura, Kenji, Fukuhara, Hideo, Fujimoto, Shimpei, Tsuda, Masayuki, Shuin, Taro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855642/
https://www.ncbi.nlm.nih.gov/pubmed/24324635
http://dx.doi.org/10.1371/journal.pone.0080850
_version_ 1782294949690081280
author Terada, Yoshio
Inoue, Keiji
Matsumoto, Tatsuki
Ishihara, Masayuki
Hamada, Kazu
Shimamura, Yoshiko
Ogata, Koji
Inoue, Kosuke
Taniguchi, Yoshinori
Horino, Taro
Karashima, Takashi
Tamura, Kenji
Fukuhara, Hideo
Fujimoto, Shimpei
Tsuda, Masayuki
Shuin, Taro
author_facet Terada, Yoshio
Inoue, Keiji
Matsumoto, Tatsuki
Ishihara, Masayuki
Hamada, Kazu
Shimamura, Yoshiko
Ogata, Koji
Inoue, Kosuke
Taniguchi, Yoshinori
Horino, Taro
Karashima, Takashi
Tamura, Kenji
Fukuhara, Hideo
Fujimoto, Shimpei
Tsuda, Masayuki
Shuin, Taro
author_sort Terada, Yoshio
collection PubMed
description BACKGROUND/AIMS: Nephrotoxicity is a frequent and major limitation in cisplatin (CDDP)-based chemotherapy. 5-Aminolevulinic acid (ALA) is widely distributed in animal cells, and it is a precursor of tetrapyrole compounds such as heme that is fundamentally important in aerobic energy metabolism. The aim of this study is to evaluate the protective role of ALA in CDDP-induced acute kidney injury (AKI). METHOD: We used CDDP-induced AKI rat model and cultured renal tubular cells (NRK-52E). We divided four groups of rats: control, CDDP only, CDDP + ALA(post);(ALA 10 mg/kg + Fe in drinking water) after CDDP, CDDP + ALA(pre & post). RESULT: CDDP increased Cr up to 6.5 mg/dl, BUN up to 230 mg/dl, and ALA significantly reduced these changes. ALA ameliorates CDDP-induced morphological renal damages, and reduced tubular apoptosis evaluated by TUNEL staining and cleaved caspase 3. Protein and mRNA levels of ATP5α, complex(COX) IV, UCP2, PGC-1α in renal tissue were significantly decreased by CDDP, and ALA ameliorates reduction of these enzymes. In contrast, Heme Oxigenase (HO)-1 level is induced by CDDP treatment, and ALA treatment further up-regulates HO-1 levels. In NRK-52E cells, the CDDP-induced reduction of protein and mRNA levels of mitochondrial enzymes was significantly recovered by ALA + Fe. CDDP-induced apoptosis were ameliorated by ALA + Fe treatment. Furthermore, we evaluated the size of transplantated bladder carcinoma to the rat skin, and ALA did not change the anti cancer effects of CDDP. CONCLUSION: These data suggested that the protective role of ALA in cisplatin-induced AKI is via protection of mitochondrial viability and prevents tubular apoptosis. Also there are no significant effects of ALA on anticancer efficiency of CDDP in rats. Thus, ALA has the potential to prevent CDDP nephrotoxicity without compromising its anticancer efficacy.
format Online
Article
Text
id pubmed-3855642
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38556422013-12-09 5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo Terada, Yoshio Inoue, Keiji Matsumoto, Tatsuki Ishihara, Masayuki Hamada, Kazu Shimamura, Yoshiko Ogata, Koji Inoue, Kosuke Taniguchi, Yoshinori Horino, Taro Karashima, Takashi Tamura, Kenji Fukuhara, Hideo Fujimoto, Shimpei Tsuda, Masayuki Shuin, Taro PLoS One Research Article BACKGROUND/AIMS: Nephrotoxicity is a frequent and major limitation in cisplatin (CDDP)-based chemotherapy. 5-Aminolevulinic acid (ALA) is widely distributed in animal cells, and it is a precursor of tetrapyrole compounds such as heme that is fundamentally important in aerobic energy metabolism. The aim of this study is to evaluate the protective role of ALA in CDDP-induced acute kidney injury (AKI). METHOD: We used CDDP-induced AKI rat model and cultured renal tubular cells (NRK-52E). We divided four groups of rats: control, CDDP only, CDDP + ALA(post);(ALA 10 mg/kg + Fe in drinking water) after CDDP, CDDP + ALA(pre & post). RESULT: CDDP increased Cr up to 6.5 mg/dl, BUN up to 230 mg/dl, and ALA significantly reduced these changes. ALA ameliorates CDDP-induced morphological renal damages, and reduced tubular apoptosis evaluated by TUNEL staining and cleaved caspase 3. Protein and mRNA levels of ATP5α, complex(COX) IV, UCP2, PGC-1α in renal tissue were significantly decreased by CDDP, and ALA ameliorates reduction of these enzymes. In contrast, Heme Oxigenase (HO)-1 level is induced by CDDP treatment, and ALA treatment further up-regulates HO-1 levels. In NRK-52E cells, the CDDP-induced reduction of protein and mRNA levels of mitochondrial enzymes was significantly recovered by ALA + Fe. CDDP-induced apoptosis were ameliorated by ALA + Fe treatment. Furthermore, we evaluated the size of transplantated bladder carcinoma to the rat skin, and ALA did not change the anti cancer effects of CDDP. CONCLUSION: These data suggested that the protective role of ALA in cisplatin-induced AKI is via protection of mitochondrial viability and prevents tubular apoptosis. Also there are no significant effects of ALA on anticancer efficiency of CDDP in rats. Thus, ALA has the potential to prevent CDDP nephrotoxicity without compromising its anticancer efficacy. Public Library of Science 2013-12-06 /pmc/articles/PMC3855642/ /pubmed/24324635 http://dx.doi.org/10.1371/journal.pone.0080850 Text en © 2013 Terada et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Terada, Yoshio
Inoue, Keiji
Matsumoto, Tatsuki
Ishihara, Masayuki
Hamada, Kazu
Shimamura, Yoshiko
Ogata, Koji
Inoue, Kosuke
Taniguchi, Yoshinori
Horino, Taro
Karashima, Takashi
Tamura, Kenji
Fukuhara, Hideo
Fujimoto, Shimpei
Tsuda, Masayuki
Shuin, Taro
5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo
title 5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo
title_full 5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo
title_fullStr 5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo
title_full_unstemmed 5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo
title_short 5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo
title_sort 5-aminolevulinic acid protects against cisplatin-induced nephrotoxicity without compromising the anticancer efficiency of cisplatin in rats in vitro and in vivo
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855642/
https://www.ncbi.nlm.nih.gov/pubmed/24324635
http://dx.doi.org/10.1371/journal.pone.0080850
work_keys_str_mv AT teradayoshio 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo
AT inouekeiji 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo
AT matsumototatsuki 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo
AT ishiharamasayuki 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo
AT hamadakazu 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo
AT shimamurayoshiko 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo
AT ogatakoji 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo
AT inouekosuke 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo
AT taniguchiyoshinori 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo
AT horinotaro 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo
AT karashimatakashi 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo
AT tamurakenji 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo
AT fukuharahideo 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo
AT fujimotoshimpei 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo
AT tsudamasayuki 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo
AT shuintaro 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo